It also inspired other studies exploring the use of ASOs to treat CLN3 juvenile Batten disease, and preclinical studies using ASOs to treat CLN3 mutations are already underway [37,38]. This evidence concerns the gene CLN3 and juvenile neuronal ceroid lipofuscinosis.